|
|
Article: Emisphere Technologies, Inc. Announces Preliminary Results From First Clinical Evaluation of Oral Heparin Capsule Dosage Form.
- Article from:
- PR Newswire
- Article date:
- April 19, 2000
CopyrightCOPYRIGHT 2000 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
TARRYTOWN, N.Y., April 19 /PRNewswire/ --
Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced preliminary clinical data confirming pre- clinical findings that its technology can effect adequate oral heparin delivery in a capsule dosage form.
In this study a solid dosage form of heparin and Emisphere's proprietary carrier, SNAC, facilitated a two fold increase in anti-coagulant response at doses comparable to doses of heparin and carrier being evaluated in the Company's current Phase III program. No significant adverse events were reported and the capsules were extremely well tolerated. Additional samples are being analyzed and final study ...